Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

NCT07150377 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Shandong First Medical University as lead sponsor.

NCT NCT07150377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07150377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma
Lead sponsor
The Second Affiliated Hospital of Shandong First Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 24, 2025
Completion date
August 24, 2028
Enrollment
41 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)